What are the 5 stages of bladder health? We've talked a little bit about the Man vs Prostate campaign, and it's really important that it's built upon a principle of linguistic determinism. We really ...

“What this means for patients is that thiazides remain an important option in the toolkit for preventing kidney stone recurrence,” says Ryan S. Hsi, MD, FACS.

In this interview, Michael S. Cookson, MD, MMHC, FACS, touches on the current and future applications of PSMA-PET imaging in prostate cancer. Cookson, who is a professor and the Donald D. Albers ...

“With the Expanded Access Program, it is an opportunity for patients to receive the drug in real-world practice,” says Sarah P. Psutka, MD, MSc.

“Some of the main implications for urologists is that the risk adapted utilization of BCG, which has been implemented as guidelines, should continue,” says Madison M. Wahlen. In this video, Madison M.

A panelist discusses how Non-muscle Invasive Bladder Cancer (NMIBC) treatment varies by risk stratification (low, intermediate, and high-risk), with BCG immunotherapy being standard for high-risk ...

“In some ways, it can be used to help if you want to get a biopsy to prove or confirm—it can be used to help detect in that range, too,” says Michael S. Cookson, MD, MMHC, FACS.

"There's a ton of activity in this space, and I think every 6 to 12 months, we're going to keep getting these boluses of information that's going to help us," says Gautam Jayram, MD.

“Our study highlights the potential of epigenomic profiling from a simple blood draw to provide a real-time, non-invasive readout of PSMA expression that corresponds with treatment response," says ...

“The median DOR of 47.8 months in patients who achieved complete response with JELMYTO provides evidence of robust durability in maintaining control of low-grade UTUC over an extended period,” says ...

"What's unique about our conference is the focus is not on just showcasing what our institute has to offer; the real focus is on networking and collaborating with the top institutes in the nation," ...

GCN2 supports prostate cancer growth by maintaining amino acid homeostasis, crucial for tumor progression. Inhibition of GCN2 alone activates p53, leading to cell cycle arrest and senescence, ...